GLPG
Galapagos NV
Company Overview
| Mkt Cap | $1.98B | Price | $28.93 |
| Volume | 249.52K | Change | +0.00% |
| P/E Ratio | 26.7 | Open | $29.00 |
| Revenue | $275.6M | Prev Close | $28.93 |
| Net Income | $74.1M | 52W Range | $22.59 - $37.78 |
| Div Yield | N/A | Target | $31.83 |
| Overall | 50 | Value | 60 |
| Quality | -- | Technical | 40 |
No chart data available
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Latest News
Kepler Capital Reaffirms Their Sell Rating on Galapagos (0JXZ)
Barclays Sticks to Its Sell Rating for Galapagos (0JXZ)
Bernstein Sticks to Their Hold Rating for Galapagos (0JXZ)
Kepler Capital Keeps Their Sell Rating on Galapagos (0JXZ)
Galapagos Discloses Bank of America’s Stake Drop Below 5% Threshold
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLPG | $28.93 | 0% | 249.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |